Purpose: To evaluate the safety and efficacy of a next-generation balloon-expandable stent-graft for the treatment of arterial occlusive disease in patients with de novo or restenotic lesions in the common and/or external iliac arteries. Methods: A prospective, multicenter, single-arm safety and efficacy study (ClinicalTrials.gov identifier: NCT02080871) of the VBX Stent Graft for treatment of de novo or restenotic lesions in the iliac arteries was conducted under an Investigational Device Exemption at 26 US sites and 1 New Zealand center. The study eligibility criteria were established with the aim of enrolling more “real-world” patients compared with previous iliac stent studies supporting Food and Drug Administration approval. The study enrolled 134 patients (mean age 66±9.5 years; 79 men) with 213 iliac lesions. Three-quarters of the population (101, 75.4%) had Rutherford category 3 ischemia, and 43 (32.1%) patients presented with TASC II C/D lesions. The primary endpoint was a composite of device- or procedure-related death within 30 days, myocardial infarction within 30 days, target lesion revascularization (TLR) within 9 months, and amputation above the metatarsals in the treated leg within 9 months. Results: In all, 234 devices were implanted in 213 lesions with 100% technical success; 57 (42.5%) patients received kissing stents at the aortic bifurcation. No devices exhibited a discernable change in length after final deployment as determined by independent core laboratory quantitative angiographic analysis. At 9 months, 3 (2.3%) of 132 patients (1 lost to follow-up, 1 unrelated death) experienced a major adverse event (3 TLRs) related to the primary endpoint. At 9 months, there were no device-related serious adverse events or unanticipated adverse device effects. Conclusion: The next-generation balloon-expandable stent-graft demonstrated notable 9-month safety and efficacy in treating iliac occlusive disease in patients reflecting common clinical practice.
KumarV.Defining the role of covered stents in aortoiliac interventions. Interv Cardiol. 2013;5:45–52.
2.
AndersonJLHalperinJLAlbertNMet alManagement of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:1425–1443.
3.
TASC Steering Committee, JaffMRWhiteCJet alAn update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:663–677.
4.
NorgrenLHiattWRDormandyJAet alInter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
5.
ConteMSPomposelliFBClairDGet alSociety for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 suppl):2S–41S.
RossiMIezziR.Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease. Cardiovasc Intervent Radiol. 2014;37:13–25.
8.
TenderaMAboyansVBartelinkMLet alESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851–2906.
9.
BosiersMIyerVDelooseKet alFlemish experience using the Advanta V12 stent-graft for the treatment of iliac artery occlusive disease. J Cardiovasc Surg (Torino). 2007;48:7–12.
10.
GilesHLesarCErdoesLet alBalloon-expandable covered stent therapy of complex endovascular pathology. Ann Vasc Surg. 2008;22:762–768.
11.
GrimmeFASpithovenJHZeebregtsCJet alMidterm outcome of balloon-expandable polytetrafluoroethylene-covered stents in the treatment of iliac artery chronic occlusive disease. J Endovasc Ther. 2012;19:797–804.
12.
GrimmeFASpithovenJHZeebregtsCJet alEndovascular treatment of occlusive lesions in the aortic bifurcation with kissing polytetrafluoroethylene covered stents. J Vasc Interv Radiol. 2015;26:1277–1284.
13.
LammerJDakeMDBleynJet alPeripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. Radiology. 2000;217:95–104.
14.
MwipatayiBPThomasSWongJet alA comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011;54:1561–1570.
15.
PsacharopuloDFerreroEFerriMet alIncreasing efficacy of endovascular recanalization with covered stent graft for TransAtlantic Inter-Society Consensus II D aortoiliac complex occlusion. J Vasc Surg. 2015;62:1219–1226.
16.
SabriSSChoudhriAOrgeraGet alOutcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation. J Vasc Interv Radiol. 2010;21:995–1003.
17.
TewksburyRTaumoepeauLCartmillAet alOutcomes of covered expandable stents for the treatment of TASC D aorto-iliac occlusive lesions. Vascular. 2015;23:630–636.
18.
MwipatayiBPSharmaSDaneshmandAet alDurability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2016;64:83–94.e1.
19.
BekkenJAVosJAAartsRAet alDISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloon-expandable stents in the common iliac artery: study protocol for a randomized controlled trial. Trials. 2012;13:215.
20.
AggarwalVWaldoSWArmstrongEJ.Endovascular revascularization for aortoiliac atherosclerotic disease. Vasc Health Risk Manag. 2016;12:117–127.
21.
de DonatoGBosiersMSetacciFet al24-Month data from the BRAVISSIMO: A large-scale prospective registry on iliac stenting for TASC A & B and TASC C & D lesions. Ann Vasc Surg. 2015;29:738–750.
22.
SchechterMAO’BrienPJCoxMW.Retrieval of iatrogenic intravascular foreign bodies. J Vasc Surg. 2013;57:276–281.
JongkindVAkkersdijkGJYeungKKet alA systematic review of endovascular treatment of extensive aortoiliac occlusive disease. J Vasc Surg. 2010;52:1376–1383.
25.
GrimmeFAGoverdePAVan OostayenJAet alCovered stents for aortoiliac reconstruction of chronic occlusive lesions. J Cardiovasc Surg (Torino). 2012;53:279–289.
26.
HoldenAMerrileesSBuckleyBet alFirst-in-human experience with the Gore balloon-expandable covered endoprosthesis in iliac artery occlusive disease. J Endovasc Ther. 2017;21:11–18.
PiazzaMSquizzatoFSpolveratoGet alOutcomes of polytetrafluoroethylene-covered stent versus bare-metal stent in the primary treatment of severe iliac artery obstructive lesions. J Vasc Surg. 2015;62:1210–1218.e1.
33.
LevilleCDKashyapVSClairDGet alEndovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. J Vasc Surg. 2006;43:32–39.
34.
RozenmanYGilonDZelingherJet alAge- and gender-related differences in success, major and minor complication rates and the duration of hospitalization after percutaneous transluminal coronary angioplasty. Cardiology. 1996;87:396–401.
35.
SmilowitzNRKirtaneAJGuiryMet alPractices and complications of vascular closure devices and manual compression in patients undergoing elective transfemoral coronary procedures. Am J Cardiol. 2012;110:177–182.
36.
RatnamLARajaJMunnekeGJet alProspective nonrandomized trial of manual compression and Angio-Seal and StarClose arterial closure devices in common femoral punctures. Cardiovasc Intervent Radiol. 2007;30:182–188.
37.
ShethRAWalkerTGSaadWEet alQuality improvement guidelines for vascular access and closure device use. J Vasc Interv Radiol. 2014;25:73–84.
